Tony Berberabe

1 week ago | targetedonc.com | Tony Berberabe

A large international real-world study has reinforced the efficacy and safety of teclistamab-cqyv (Tecvayli) in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), including those with prior exposure to B-cell maturation antigen (BCMA)-directed therapies, according to findings published in Blood Cancer Journal.¹The retrospective analysis, conducted across 9 academic centers in 5 countries, evaluated 210 patients.

2 weeks ago | targetedonc.com | Tony Berberabe

As the United States faces a growing shortage of oncologists,1,2 the American Society of Clinical Oncology (ASCO) has efforts to attract medical students to the field through mentorship, research opportunities, and early exposure to cancer care. Many of the initiatives emphasize the importance of engaging students early in their medical training.

2 weeks ago | targetedonc.com | Tony Berberabe

Results of a phase 1 trial (NCT04074746) evaluating the combination of the bispecific antibody AFM13 and expanded natural killer (NK) cells precomplexed with AFM13 (AFM13-NK) in 42 patients with relapsed refractory lymphoma demonstrated an overall response rate (ORR) of 92.9% and a complete response (CR) rate of 66.7%.

2 weeks ago | targetedonc.com | Tony Berberabe

INVESTIGATORS AND CLINICIANS anticipate that the next wave of therapeutic approaches in renal cell carcinoma (RCC) will target hypoxia-inducible factor-2 (HIF-2), a transcription factor that is overactive in clear cell RCC. Loss of function in the VHL gene is a hallmark of clear cell RCC pathogenesis and leads to HIF overexpression.1 The pVHL functions as the substrate recognition component of an E3-ubiquitin ligase.

3 weeks ago | targetedonc.com | Tony Berberabe

Findings of the phase 2 INFINITY trial (NCT04817826) indicate that a chemotherapy-free regimen of tremelimumab (Imjudo) plus durvalumab (Imfinzi; T300/D) exhibited promising antitumor activity in patients with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H), resectable gastric/gastroesophageal junction adenocarcinoma.1 The study, published in Annals of Oncology, explored the activity and safety of T300/D in both neoadjuvant and definitive treatment settings, and...